Reduction of syndecan-1 expression during lip carcinogenesis

Journal of Oral Pathology and Medicine

Volumn 38, Issue 7, 2009, Pages 580-583

  Martínez, Alejandra ^a   Spencer, M L ^a   Brethauer, U ^a   Grez, P ^a   Marchesani, F J ^a   Rojas, I G ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Actinic cheilitis; Lip carcinogenesis; Lip squamous cell carcinoma; Syndecan 1; UV light

Indexed keywords

BIOLOGICAL MARKER; SYNDECAN 1;

ACTINIC CHEILITIS; ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; LIP; LIP BIOPSY; LIP CARCINOMA; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHEILITIS; FEMALE; HUMANS; KERATOSIS, ACTINIC; LIP; LIP NEOPLASMS; MALE; MIDDLE AGED; REFERENCE VALUES; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 70350634313     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00761.x     Document Type: Article

References (32)

1. Main JH, Pavone M. Actinic cheilitis and carcinoma of the lip. J Can Dent Assoc 1994; 60: 113-116
2. De Visscher JG, Van Der Waal I. Etiology of cancer of the lip. A review. Int J Oral Maxillofac Surg 1998; 27: 199-203.
3. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-393
4. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777
5. Steinfeld R, Van Den Berghe H, David G. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 1996; 133: 405-416
6. Sun D, Mcalmon KR, Davies JA, Bernfield M, Hay ED. Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelialmesenchymal transformation. Int J Dev Biol 1998; 42: 733-736
7. Soukka T, Pohjola J, Inki P, Happonen RP. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med 2000; 29: 308-313
8. Kurokawa H, Matsumoto S, Murata T, et al. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia. J Oral Pathol Med 2003; 32: 513-521
9. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 1996; 28: 63-67
10. Elenius K, Vainio S, Laato M, Salmivirta M, Thesleff I, Jalkanen M. Induced expression of syndecan in healing wounds. J Cell Biol 1991; 114: 585-595
11. Kurokawa H, Zhang M, Matsumoto S, et al. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma. J Oral Pathol Med 2006; 35: 301-306
12. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecans at specific stages of differentiation. Cell Regul 1989; 1: 27-35.
13. Má thé M, Suba Z, Nemeth Z, et al. Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 2006; 42: 493-500.
14. Mukunyadzi P, Liu K, Hanna EY, Suen JY, Fan CY. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 2003; 16: 796-801.
15. Ro Y, Muramatsu T, Shima K, et al. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue. Int J Oral Maxillofac Surg 2006; 35: 252-257
16. Burbach BJ, Friedl A, Mundhenke C, Rapraeger AC. Syndecan-1 accumulates in lysosomes of poor differentiated breast carcinoma cells. Matrix Biol 2003; 22: 163-177
17. Wiksten JP, Lundin J, Nordling S, et al. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 2001; 95: 1-6.
18. Conejo JR, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000; 88: 12-20.
19. Bayer-Garner IB, Dilday B, Sanderson RD, Smoller BR. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma. Am J Dermatopathol 2000; 22: 119-122
20. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast cancer is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-483
21. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rampamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005; 65: 3226-3235
22. Inki P, Stenba? ck F, Talve L, Jalkanen M. Immunohistochemical localization of syndecan-1 in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation. Am J Pathol 1991; 139: 1333-1340
23. Inki P, Stenba? ck F, Grenman S, Jalkanen M. Immunohistochemical localization of syndecan-1 in normal and pathological human uterin cervix. J Pathol 1994; 172: 349-355
24. Kaugars GE, Pillion T, Svirsky JA, Page DG, Burns JC, Abbey LM. Actinic cheilitis: a review of 152 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 181-186
25. Martínez A, Brethauer U, Rojas IG, et al. Expression of apoptotic and cell proliferation regulatory protein in actinic cheilitis. J Oral Pathol Med 2005; 34: 257-262
26. Rojas IG, Martínez A, Pineda A, Spencer ML, Jiménez M, Rudolph MI. Increased mast cell density and protease content in actinic cheilitis. J Oral Pathol Med 2004; 33: 567-573
27. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77: 1033-1079
28. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10: 309-318
29. Rojas IG, Spencer ML, Martínez A, Maurelia M, Rudolph MI. Characterization of mast cell subpopulations in lip cancer. J Oral Pathol Med 2005; 34: 268-273
30. Kobayashi R, Okamura S, Ohno T, et al. Hyperexpression of FcgammaRI and Toll-like receptor 4 in the intestinal mast cell of Crohn's disease patients. Clin Immunol 2007; 125: 149-158
31. Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 1999; 44: 2508-2515
32. Day RM, Mitchell TJ, Knight SC, Forbes A. Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine 2003; 21: 224-233